---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-274082"
form_type: "8-K"
ticker: "PHAT"
cik: "0001783183"
company_name: "Phathom Pharmaceuticals, Inc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T07:17:18.230688+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Phathom Q3 net loss $43.2M; VOQUEZNA FDA approved for Erosive GERD; Dec launch

## Summary
- Net loss $43.2M in Q3 2023 vs $51.1M in Q3 2022; includes $6.1M stock-based compensation.
- Cash $213.7M at Sep 30; $175M from revenue interest financing plus $100M Hercules loan available.
- FDA approved VOQUEZNA (vonoprazan) for Erosive GERD in Nov 2023; launch expected Dec 2023.
- NDA submitted for vonoprazan as daily Non-Erosive GERD treatment in Sep 2023; FDA action Q3 2024.
- Phase 3 As Needed NERD trial to start in 2024; cash expected to fund ops through end of 2025.

## SEC filing metadata
- accession: 0001193125-23-274082
- form_type: 8-K
- ticker: PHAT
- cik: 0001783183
- company_name: Phathom Pharmaceuticals, Inc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783183/000119312523274082/0001193125-23-274082-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783183/000119312523274082/d593359d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-274082
- JSON: https://secwatch.observer/filing/0001193125-23-274082.json
- Plain text: https://secwatch.observer/filing/0001193125-23-274082.txt

## Key facts
- Earnings Releases
  Phathom Pharmaceuticals, Inc. reported the third quarter of 2023 results: net income $43.2 million.
  - Period: the third quarter of 2023
  - Net income: $43.2 million
  - Result: reported results
  source text: Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported financial results for the third quarter of 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1783183/000119312523274082/0001193125-23-274082-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.